Better Health for All

ALX Oncology's core business is developing novel cancer therapies, with its entire pipeline focused on treating cancer and extending patients' lives.

While its evorpacept therapy failed to meet primary endpoints in two Phase 2 trials for head and neck squamous cell carcinoma, it demonstrated an 83% complete response rate in indolent relapsed/refractory B-cell Non-Hodgkin Lymphoma, compared to a 34% historical rate. It also showed a 56% response rate and 7.4 months median progression-free survival in HER2-positive breast cancer patients. The company's investigational therapies have shown a well-tolerated safety profile in a randomized trial and a manageable safety profile in combination therapies, with no dose-limiting toxicities observed in the prior two dose cohorts for ALX2004. However, the combination of evorpacept and zanidatamab showed a manageable safety profile in patients who had received a median of six prior therapies, including Enhertu. The company laid off 30% of its workforce in early March 2025 and reduced preclinical research to focus on evorpacept trials. ALX Oncology's Code of Business Conduct and Ethics, adopted June 25, 2020, requires compliance with environmental laws and aims to minimize environmental impacts. The Code also outlines responsible handling of nonpublic information and requires employees to sign a Confidential Information Agreement. The company provides a whistleblower hotline and web portal for reporting violations. It has an expanded access policy stating it does not currently offer access to evorpacept outside of clinical studies.

Fair Pay & Worker Respect

No specific, quantitative evidence was found in the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. Information regarding employee benefits, compensation philosophy, and governance structures was present, but lacked the precise numerical data required by the rubric's quantitative thresholds for living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage percentage.

For example, while a reduction in workforce was mentioned, it does not constitute voluntary turnover. Similarly, general statements about competitive benefits or non-discrimination policies do not provide the specific percentages or ratios needed for scoring.

Fair Trade & Ethical Sourcing

No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. ALX Oncology adopted a Code of Business Conduct and Ethics on June 25, 2020.

which provides a general statement of ethical expectations for its directors, employees, officers, and contractors. However, the articles do not provide data on fair-trade certifications, supplier audit frequencies, incidents of forced or child labor, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, materials risk, or supplier diversity spend.

Honest & Fair Business

ALX Oncology Holdings Inc. has a Code of Business Conduct, adopted on June 25, 2020, which includes a whistleblower policy.

This policy allows employees to report violations via an online web portal or phone and prohibits retaliation against individuals who report in good faith. The company states it will promptly investigate suspected violations, but there is no evidence of independent investigation processes. All directors, officers, and employees are required to sign an annual acknowledgment form confirming their understanding and agreement to comply with the Code. The company's SEC filings, including the Form 10-Q as of September 30, 2024, make no mention of financial restatements, and disclosure controls and procedures were deemed effective. The Code of Business Conduct includes sections on compliance with the Foreign Corrupt Practices Act (FCPA) and related anti-corruption laws, prohibiting bribery to obtain or retain business, but the articles do not provide information on training frequency or effectiveness metrics for this policy.

Kind to Animals

ALX Oncology Holdings Inc. conducts pre-clinical studies of its drugs on animals to assess product safety, including using animal models in leukemia research.

The company has significant involvement in animal testing, with evidence of using animals for tumor elimination and prolonged survival studies. There is no explicit mention of a formal animal testing policy or any commitment to reduce animal testing. The company's preclinical studies involve animal models, and there is no data on the number of animals used, which, in the absence of any reported reduction or alternative methods, maps to the highest negative tier for volume.

No War, No Weapons

The provided articles consistently describe ALX Oncology as a clinical-stage immuno-oncology company focused on developing cancer therapies.

However, none of the articles contain specific, concrete data points or explicit statements regarding the company's involvement, or lack thereof, in arms manufacturing, military contracts, dual-use technologies, sales to sanctioned regimes, peacebuilding investments, or any other metrics related to the 'No War, No Weapons' value. The articles explicitly state that information for all relevant KPIs is not provided. Therefore, no KPIs can be scored based on the evidence.

Planet-Friendly Business

No specific, quantitative data points are available in the provided articles to assess ALX Oncology Holdings Inc. against the Planet-Friendly Business KPIs. Article 1 explicitly states that carbon emissions data, reduction targets, renewable energy use, water use, waste diversion, and other environmental metrics are not publicly available or are missing.

There is no evidence of certifications, awards, or regulatory actions.

Safe & Smart Tech

The company's privacy policy, updated January 8, 2025, outlines user rights to access, update, and delete data.

No other specific information regarding data protection, cybersecurity, or AI ethics is available.

Zero Waste & Sustainable Products

The provided articles, primarily financial reports, do not contain specific, quantifiable data for any of the 'Zero Waste & Sustainable Products' KPIs.

While one article outlines the company's policy to conduct business in an environmentally responsible way, minimize environmental impacts, reduce waste generation, and dispose of waste safely, these are stated goals and policies, not measurable outcomes, specific initiatives, or reported results. No evidence is provided regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management performance, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.